Pathology: mHCC - 1st line (L1);
| mHCC - 1st line (L1) | |||||||||||
| IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | HIMALAYA, 2022 | CheckMate 459, 2019 | CheckMate 9DW, 2024 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | ||
| durvalumab plus bevacizumab | 1 | T1 | |||||||||
| nivolumab plus ipilimumab plus SoC | 1 | T1 | |||||||||
| Tislelizumab | 1 | T1 | |||||||||
| atezolizumab plus cabozantinib | 1 | T1 | |||||||||
| camrelizumab based treatment | 1 | T1 | |||||||||
| pembrolizumab plus lenvatinib | 1 | T1 | |||||||||
| durvalumab plus tremelimumab | 1 | T1 | |||||||||
| sintilimab | 1 | T1 | |||||||||
| atezolizumab plus bevacizumab | 1 | T1 | |||||||||
| nivolumab alone | 1 | T1 | |||||||||
| placebo | 0 | T0 | |||||||||
| VEGF(R) inhibitor | 0 | T0 | |||||||||
| lenvatinib | 0 | T0 | |||||||||
| sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | |||